

Metabolic syndrome in women with and without polycystic syndrome, A case control study in Iran

Farzaneh Montazerifar^{*1}, Marzieh Ghasemi², Nafiseh Arabpour³, Mansour Karajibani⁴, Narjes Keikhah⁵

^{*1} Pregnancy Health Research Center, Nutrition Department, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

² Pregnancy Health Research Center, Obstetrics and Gynecology Department, Zahedan University of Medical Sciences, Zahedan, Iran

³ School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

⁴ Health Promotion Research Center, Nutrition Department, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

⁵ Department of Anatomical Sciences, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

⁶ School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

Received: 4 May 2020 Accepted: 24 Jun 2020

Abstract

Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of fertility age. The aim of this study was to compare the prevalence of metabolic syndrome (MetS) in women with and without PCOS, who referred to infertility clinic.

Methods: In this case control study, 120 women with PCOS and 120 healthy controls, who had referred to infertility clinic, were selected for the purpose of this study. Polycystic ovarian disease was diagnosed according to the Rotterdam (2003) criteria, and the prevalence of MetS was assessed according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria for both groups.

Results: Women with PCOS had markedly higher prevalence of the MetS than healthy controls (29.2% and 7.5%, respectively; $P < 0.0001$). Among risk factors of MetS, the most prevalent components were low level of HDL cholesterol (97.5%), central obesity (86.7%), and high triglyceride (77.5%). The prevalence of MetS increased with age and BMI ($P < 0.0001$).

Conclusion: The results suggest that the MetS was more frequent in PCOs infertile women, especially in upper age groups. Thus, the screening of these patients is suggested for preventive strategies in high risk individuals.

Keywords: Infertility, Metabolic syndrome, Polycystic ovary syndrome, Prevalence

Introduction

Polycystic ovary syndrome (PCOS) is the most common endocrine disturbance in women of reproductive age, leading to infertility (1). The prevalence of PCOS has been reported to be around 6–20% in different countries (2, 3). Studies have shown that women with PCOS are at high risk of metabolic

disorders and type 2 diabetes (4, 5) and an increased risk of cardiovascular disease, which is seen in obese women with the disorder (1). Metabolic syndrome, one type of endocrine disorder and a cardiovascular risk factor, is mainly observed with insulin resistance, hyperinsulinemia, dyslipidemia, abdominal obesity, and hypertension (6, 7). Many disorders caused by PCOS are similar to MetS components (6, 7). A high

***Correspondence author:** Dr. Montazerifar: Department of Nutrition, School of Medicine, Zahedan University of Medical

Sciences, Zahedan, Iran Tel: +98- 9155416903 Fax: +98- 54-33295728

E-mail: fmontazerifar@gmail.com

prevalence of diabetes mellitus and impaired fasting glucose, hypercholesterolemia, high triglyceride and low HDL (8-10), the prevalence of obesity in women with PCOS (9-12), hypertension and infertility prevalence in obese women with PCOS compared to those with normal weight have been reported in several studies (12). Studies on the prevalence of MetS in Iranian women with PCOS and those of other countries have reported varied data from 19.7% - 46.4% in Iran (1, 5, 8, 13), 37.5% - 47.5% in India (9, 10) and 43-46% in the US (14, 15). There is, nevertheless, one study conducted on Iranian women reporting that metabolic syndrome in women with PCOS was no more common than in healthy controls (13). The contradictory results on the prevalence of MetS of women with PCOS in Iran and other countries demonstrate that more research is needed to be done in this area. Thus, this study was performed to determine the prevalence of MetS and its risk factors in women with and without PCOS, who had referred to infertility clinic in Zahedan, Iran.

Materials & Methods

This study was supported by the Research Deputy of Zahedan University of Medical Sciences, Zahedan, Iran (approval date: January 2018; number 8624). The protocol of the study was approved by the Ethics Committee of Zahedan University of Medical Sciences (Code No: IR.ZAUMS.REC.1396.308).

This case control study was conducted on 120 women with PCOS and 120 healthy controls attending the infertility clinic in Zahedan, Iran. The study was carried out between March, 2018, and April, 2019. Informed consent forms were also given to all the participants. The control group comprised infertile women without PCOS, whose infertility was due to their husbands. All consecutive women with and without PCOS were matched based on age and body mass indices (BMI).

The Rotterdam criteria (2003), used for the diagnosis of PCOS, had at least two of the following features: (i) oligo-ovulation or chronic an ovulation, (ii) clinical and/or biochemical hyperandrogenism, and (iii) ultrasound appearance of polycystic ovaries (9,16).

The inclusion criteria were as follows: 15-45 years of age, no use of steroid or oral contraceptive drugs within 3 months prior to the onset of the study, the history of diabetes, the use of anti-diabetic and anti-lipid medications, hypertension, androgen secreting tumors, thyroid and renal disorders, hyperprolactinemia, and Cushing's syndrome.

The anthropometric measurements and the blood pressure of the participants were evaluated by a researcher right after obtaining the written consent forms. Their weight and height were also measured with light clothing without shoes. The BMI was calculated as weight (kg) divided by the square of height (m²) (kg/m²). Waist circumference (WC) was measured with a non-elastic tape at the narrowest circumference, midway between the top of iliac crest and the lowest rib margin. WC \geq 88 cm was considered as central obesity. BMI was stratified into two groups as follows: (1) non-obese: BMI < 25 kg/m² and (2) overweight /obese: BMI \geq 25 kg/m² (9). Age was also categorized into two subgroups: (1) < 30 year and (2) \geq 30 years. Blood pressure was measured twice using a manual mercury sphygmomanometer on the right arm in a sitting position after 10 minutes rest. The mean of two measurements was reported (9).

Overnight fasting blood sample was obtained from all women. Blood tests, including fasting blood glucose (FBS) and lipid profile (total cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) levels, were measured using enzymatic calorimetric method by Pars Azmun kits, Tehran, Iran.

The diagnosis of MetS was according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III (criteria); thus, the presence of three or more of the following five criteria was necessary: (1) waist circumference of \geq 88 cm or more, (2) blood pressure of \geq 130/85 mmHg; (3) fasting blood sugar of \geq 100 mg/dL, (4) triglycerides of \geq 150 mg/dL and (5) HDL-C of \leq 50 mg/dL (8). In addition, High LDL-C and high cholesterol were defined as LDL-C \geq 130 mg/dL and (total cholesterol \geq 200 mg/dL), respectively.

Statistical analysis

The statistical analyses were performed using SPSS software version 21 (SPSS, Inc., Chicago, IL, USA). The data were presented as mean \pm standard deviation (SD) and frequency (%). The Student's t-test and Chi-square test were used to compare the continuous and categorical variables, respectively. Kolmogorov-Smirnov test was used for evaluation of normality of distribution. Spearman's correlation coefficient was calculated to assess the association between MetS and other biomarkers. After controlling the significant variables identified by univariate analyses, a binomial logistic regression analysis with calculation of the adjusted odds ratio (OR) and 95% confidence interval (CI) was performed for the identification of independent predictors of metabolic syndrome. A P-value of <0.05 was considered significant.

Results

The anthropometric and biochemical characteristics of participants are demonstrated in Table 1. The mean age and BMI of women with PCOS were 26.3 ± 5 years and 27.9 ± 6 Kg/m², respectively, and the mean age and BMI of women without PCOS (control group) were 26.8 ± 5.4 years and 26.6 ± 5.2 Kg/m², respectively. The prevalence of metabolic syndrome was found to be

higher in women with PCOS compared to the control group (29.2% vs. 7.5%; $P < 0.0001$). Also, the women with PCOS had significantly higher values of waist circumference ($P < 0.001$) and triglyceride ($P = 0.04$) and lower levels of serum HDL-C ($P = 0.046$) than the control group.

Table 2 demonstrates the distribution of metabolic syndrome according to different categorizes of age and body mass index. The results showed that the prevalence of MetS increased with age and BMI ($P < 0.001$).

The prevalence of metabolic risk factors is shown in Table 3. The most prevalent risk factors were the low level of HDL-C (97.5%), the central obesity (86.7%), high LDL-C (80.8%), and high triglyceride (77.5%). A significant correlation was found between metabolic syndrome with WC ($r = 0.2$, $P = 0.02$), FBS ($r = 0.21$, $P = 0.02$), triglyceride ($r = 0.59$, $P < 0.001$), high LDL-C ($r = 0.21$, $P = 0.02$), and low HDL-C ($r = -0.19$, $P = 0.03$).

In a logistic regression analysis, low HDL-C (OR = 3.05, 95% CI: 1.76–5.51), high triglyceride (OR = 3.54, 95% CI: 1.57–7.99) and high WC (OR = 2.01, 95% CI: 1.01–3.88) were markedly associated with MetS (Table 4).

Table 1. Demographic, anthropometric, and metabolic characteristics in studied groups

Variables	With PCOS (n=120) Mean \pm SD	Without PCOS (n=120) Mean \pm SD	P-value
Metabolic syndrome n (%)	35 (29.2%)	9 (7.5%)	<0.001
Age (years)	26.3 ± 5	26.8 ± 5.4	0.478
Body mass index (Kg/m ²)	27.9 ± 6	26.6 ± 5.2	0.065
Waist Circumference (Cm)	99.3 ± 11.1	90.4 ± 9	<0.001
Systolic pressure (mmHg)	116.6 ± 7.5	114.6 ± 8.3	0.500
Diastolic pressure (mmHg)	79.6 ± 5.8	78 ± 6.7	0.250
Fasting blood sugar (mg/dL)	95.2 ± 14.9	94.3 ± 7.3	0.320
Cholesterol (mg/dL)	197.1 ± 22.8	191.2 ± 22.9	0.130
Triglyceride (mg/dL)	141 ± 73	120.8 ± 58.5	0.040
LDL-C (mg/dL)	110.6 ± 21.1	105.4 ± 12	0.450
HDL-C (mg/dL)	39.2 ± 3.4	49.3 ± 7.4	0.046

PCOS: polycystic ovary syndrome; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol

Table2. Distribution of metabolic syndrome according to age and body mass index categorizes

Variables	With PCOS n / Total (%)	Without PCOS n / Total (%)	P-value
Age (years)			
<30	10 / 61 (16.4%)	8 / 67 (11.9%)	0.450
≥30	25 / 59 (42.4%)	1 / 53 (1.9 %)	< 0.0001
Body mass index (Kg/m²)			
<25	7 / 33 (21.2%)	3 / 39 (7.7%)	<0.010
≥25	28 / 87 (32.2%)	6 / 81 (7.4%)	<0.0001

PCOS: polycystic ovary syndrome

Table3. Prevalence of metabolic risk factors in studied groups

Variables	With PCOS n (%)	Without PCOS n (%)	P-value
Overweight/Obese (BMI ≥25 Kg/m ²)	87(72.5%)	81(67.5%)	0.390
Central obesity (WC ≥ 88 cm)	104(86.7%)	28(23.3%)	<0.0001
Hypertension (BP ≥130/85 mmHg)	6(5%)	1(0.8%)	0.010
High FBS (≥ 100 mg/dL)	13(10.8%)	5(4.2%)	0.050
High Cholesterol (≥200 mg/dL)	64(53.3%)	32(26.7%)	<0.0001
High Triglyceride (≥150 mg/dL)	93(77.5%)	5(4.2%)	<0.0001
High LDL-C (≥130 mg/dL)	97(80.8%)	78(65.0%)	0.006
Low HDL-C (≤50 mg/dL)	111(97.5%)	3(2.5%)	<0.0001

PCOS: polycystic ovary syndrome; BMI: Body mass index; WC: waist-circumference; BP: Blood pressure; FBS: fasting glucose blood sugar; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol

Table 4. Logistic regression analysis showing the predictive association of studied variables and presence of metabolic syndrome in PCOS group

Model	Beta	P-value	Odds ratio	95% CI
Central obesity (WC ≥ 88 cm)	0.244	0.041	2.01	1.01~3.88
Hypertension (BP ≥130/85 mmHg)	0.072	0.540	0.69	0.43~1.56
High FBS (≥ 100 mg/dL)	0.222	0.089	0.66	0.48~1.09
High Cholesterol (≥200 mg/dL)	0.084	0.385	0.52	0.18~1.05
High Triglyceride (≥150 mg/dL)	0.569	0.0001	3.54	1.57~7.99
High LDL-C (≥130 mg/dL)	0.080	0.062	1.05	0.93~1.58
Low HDL-C (≤50 mg/dL)	0.007	0.001	3.05	1.76~5.51

PCOS: polycystic ovary syndrome; BMI: Body mass index; WC: waist-circumference; BP: Blood pressure; FBS: fasting glucose blood sugar; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol.

Discussion

The metabolic abnormalities in women with PCOS directly contribute to the increased risk of MetS and the development of atherosclerotic cardiovascular disease (1,9). The present study demonstrated that the prevalence of MetS in women with PCOS was 29.2%, which was according to ATPIII criteria. The results of our study are close (28.8%) to that of Zahiri et al (1) in North of Iran. It was, nonetheless, lower than the reported rate in a study performed in an urban population of Tehran (46.4%) (17), and those of several other studies in the United States (33.4–46%) (14, 15). Also, in some Asian countries such as India and Brazil, the rates were 37.9% and 28.4% (9, 10), respectively. In contrast, in several studies in Iran (5, 8, 13, 18) and several European countries, like Turkey (11.6%) (19) and southern Italy (8.2%) (20), the prevalence of MS in women with PCOS was found to be lower compared to our results. The different prevalence rates of MetS are likely to be attributed to sample size, diagnostic criteria, race, age, body mass index, and lifestyle in various populations (1, 5, 8).

Advanced age was known as a vital risk factor for metabolic syndrome in the case of PCOS and in general population as well. Our study revealed that the risk of MetS in women with PCOS increased with age, and 42.4% of women the ages ≥ 30 years had metabolic syndrome. The results of several studies have also revealed that women with both PCOS and MetS were significantly older than others (1, 5, 22). It seems that the high prevalence of MetS in aging may be partly associated with hyperinsulinemia changes in body composition and increased body fat (8). It is also known that the pattern of fat distribution in obese women is associated with the increased risk of insulin resistance, hyperandrogenism, and metabolic disorders (1,8,9).

The relationship between MetS and BMI in general population (21) and in women with PCOS (22) was revealed in earlier studies. However, it has been reported that in women with PCOS, the age and central obesity are more powerful predictors for the presence of metabolic syndrome than BMI (9). In contrast, a meta-analysis result in Iran showed that there was no significant correlation between the MetS and waist

circumference, BMI, and age (18). Our study showed that the risk of MetS increased in those with BMI ≥ 25 kg/m², as 32.2% of women with PCOS who had BMI ≥ 25 kg/m² were exposed to MetS. Similar to the findings of our study, other studies found that the prevalence of MetS increased with obesity (5, 9, 22). Also, our finding, the high value of waist circumference in women with PCOS compared to healthy controls, indicated that WC was closely correlated with MetS. This finding was consistent with those of the earlier studies (9,23).

Among the biochemical parameters that were measured in our study, the level of serum triglyceride was markedly higher and the HDL- C level was markedly lower in women with PCOS compared to healthy controls. Dyslipidemia was present with a low level of HDL-C in 97.5% of women with PCOS, followed by increased triglyceride in 77.5%.

In previous studies, the most prevalent components of MetS in women with PCOS were different. However, in line with our findings, several studies have reported that the most prevalent risk factors of MetS in women with PCOS were the low level of HDL-C, high triglyceride, and the increased WC (24,25). Low levels of HDL-C, as a component of MetS, has a crucial role in the development of cardiovascular diseases (1,5, 22). In our study, the multivariate logistic regression analysis showed that central obesity, low HDL-C, and high triglyceride were more powerful predictors of metabolic syndrome in women with PCOS compared to other risk factors of MetS.

The present study has some limitations. This study was performed with low sample size. For a more accurate estimate, a greater sample size is needed. Also, the evaluation of body composition, physical activity, and dietary intake are essential for preventive planning.

Conclusion

The results suggest that obese women with PCOS in upper age groups are at a greater risk of metabolic disorders. The identification of risk factors for screening can be a substitute strategy. Further

investigations for the screening of metabolic syndrome in women with PCOS are highly required.

Acknowledgements

The authors would like to acknowledge the women who participated in the study.

Conflicts of Interest

The authors have no competing interests.

References

1. Zahiri Z, Sharami H, Milani F, Mohammadi F, Kazemnejad E, Ebrahimi H, Heirati F. Metabolic syndrome in patients with polycystic ovary syndrome in Iran. *Int J Fertil Steril* 2016; 9(4): 490–496.
2. Echiburú B, Crisosto N, Maliqueo M, Pérez-Bravo F, de Guevara AL, Hernández P, et al. Metabolic profile in women with polycystic ovary syndrome across adult life. *Metabolism*. 2016; 65(5):776-82.
3. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. *Fertility and sterility*. 2016; 106(1):6-15.
4. Lankarani M, Valizadeh N, Heshmat R, Peimani M, Sohrabvand F. Evaluation of insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome. *Gynecological Endocrinology*. 2009;25(8):504-7.
5. Moini A, Javanmard F, Eslami B, Aletaha N. Prevalence of metabolic syndrome in polycystic ovarian syndrome women in a hospital of Tehran. *Iranian J Reprod med*. 2012; 10(2):127.
6. Papadakis G, Kandaraki E, Papalou O, Vryonidou A, Diamanti-Kandarakis E. Is cardiovascular risk in women with PCOS a real risk? Current insights. *Minerva endocrinologica*. 2017; 42(4):340.
7. Ollila MM, West S, Keinänen-Kiukaanniemi S, Jokelainen J, Auvinen J, Puukka K, et al. Overweight and obese but not normal weight women with PCOS are at increased risk of Type 2 diabetes mellitus—a prospective, population-based cohort study. *Human Reproduction*. 2017; 32(2):423-31.
8. Madani, Hosseini R, Ramezanal F, Khalili GH, Jahangiri, Ahmad J, Rastegar F, Zolfaghari Z. Metabolic syndrome in infertile women with polycystic ovarian syndrome. *Arch Endocrinol Metab* 2016; 60 (3):199-204
9. Mandrelle K, Kamath MS, Bondu DJ, Chandy A, Aleyamma TK, George K. Prevalence of metabolic syndrome in women with polycystic ovary syndrome attending an infertility clinic in a tertiary care hospital in south India. *J Hum Reprod Sci*. 2012; 5(1): 26–31.
10. Bhattacharya SM. Prevalence of metabolic syndrome in women with polycystic ovary syndrome, using two proposed definitions. *Gynecol Endocrinol* 2010; 26 (7):516-20
11. Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. *Hum reprod* 2012; 18(6):618-37.
12. Sharami S H, Fakor F, Mohammadi F, Molaei R, Shakiba M, Dalil Heirati S F, et al. Comparison of the Clinical and Laboratory Features of Polycystic Ovary Syndrome of Women with Normal weight with Overweight and Obese Women. *J Babol Uni Med Sci*. 2015; 17 (2) :21-8
13. Hosseinpanah F, Barzin M, Tehrani FR, Azizi F. The lack of association between polycystic ovary syndrome and metabolic syndrome: Iranian PCOS prevalence study. *Clin Endocrinol* 2011; 75(5):692-7.
14. Apridonize T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. *J Clin Endocrinol Metab*. 2005; 90:1929–1935.
15. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. *Metabolism*. 2003;52(7):908-15
16. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term

- health risks related to polycystic ovary syndrome (PCOS). *Hum Reprod* 2004; 19(1): 41–7.
17. Moradi S, Darvishi N. Evaluation of the Prevalence of Metabolic Syndrome in Women with Polycystic Ovary Syndrome Referred to the Institute of Endocrine and Metabolism. *J Iran Uni Med Sci* 2009; 16(63) (Persian).
 18. Niksima H, Odel NM, Khakli S, Ghanei R, Fallahi A eKurdi A. Prevalence of metabolic syndrome among Iranian women with polycystic ovary syndrome: A systematic review and meta-analysis. *Diabetes Metab Syndrome: Clin Res Rev* 2019; 13(3):1911-15.
 19. Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. *Hum Reprod*. 2005; 20(9):2409-13.
 20. Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. *Eur J Endocrinol*. 2006; 154(1):141-5.
 21. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. *Arch Intern Med*. 2003;163(4):427-36.
 22. Soares EM, Azevedo GD, Gadelha RG, Lemos TM, Maranhão TM. Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome. *Fertil Steril*. 2008; 89(3):649-55.
 23. Janssen I, Katzmarzyk PT, Ross P. Waist circumference and not body mass index explains obesity related health risks. *Am J Clin Nutr*. 2004; 74:379–84
 24. Marcondes JA, Hayashida SA, Barcellos CR, Rocha MP, Maciel GA, Baracat EC. Metabolic syndrome in women with polycystic ovary syndrome: prevalence, characteristics and predictors. *Arq Bras Endocrinol Metabol*. 2007; 51(6):972-9. 32.
 25. Espínós-Gómez JJ, Rodríguez-Espinosa J, Ordóñez-Llanos J, Calaf-Alsina J. Metabolic syndrome in Mediterranean women with polycystic ovary syndrome: when and how to predict its onset. *Gynecol Endocrinol*. 2012; 28(4):264-8.